High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo. Brigger D, Guntern P, Pennington LF, van Brummelen R, et al. J Allergy Clin Immunol 2025 Jul 16:S0091-6749(25)00623.

Read + Share

Amedeo Smart

Independent Medical Education

Brigger D, Guntern P, Pennington LF, van Brummelen R, et al. High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo. J Allergy Clin Immunol 2025 Jul 16:S0091-6749(25)00623.
PMID: 41081658